Unknown

Dataset Information

0

Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.


ABSTRACT: To describe factors associated with multidrug-resistant (MDR), including extensively-drug-resistant (XDR), tuberculosis (TB) in the United States, we abstracted inpatient, laboratory, and public health clinic records of a sample of MDR TB patients reported to the Centers for Disease Control and Prevention from California, New York City, and Texas during 2005-2007. At initial diagnosis, MDR TB was detected in 94% of 130 MDR TB patients and XDR TB in 80% of 5 XDR TB patients. Mutually exclusive resistance was 4% XDR, 17% pre-XDR, 24% total first-line resistance, 43% isoniazid/rifampin/rifabutin-plus-other resistance, and 13% isoniazid/rifampin/rifabutin-only resistance. Nearly three-quarters of patients were hospitalized, 78% completed treatment, and 9% died during treatment. Direct costs, mostly covered by the public sector, averaged $134,000 per MDR TB and $430,000 per XDR TB patient; in comparison, estimated cost per non-MDR TB patient is $17,000. Drug resistance was extensive, care was complex, treatment completion rates were high, and treatment was expensive.

SUBMITTER: Marks SM 

PROVIDER: S-EPMC4012799 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC2630755 | biostudies-literature
| S-EPMC3086214 | biostudies-literature
| S-EPMC7350275 | biostudies-literature
| S-EPMC5801661 | biostudies-literature
| S-EPMC4521689 | biostudies-other
| S-EPMC5495008 | biostudies-other
| S-EPMC6830138 | biostudies-literature
| S-EPMC8669042 | biostudies-literature
| S-EPMC7045844 | biostudies-literature
| S-EPMC5527618 | biostudies-literature